TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33773577

Group type: EXPERIMENTAL
Intervention: Combined protocol (lidocaine + Huffing maneuver)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Huffing maneuver
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 400
Study: 35675229

Group type: EXPERIMENTAL
Intervention: Probiotic Lacticaseibacillus rhamnosus HN001
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 35530165

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study: 33657294

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 36194311

Group type: EXPERIMENTAL
Intervention: Talk-to-Me MOOC
Number of subjects: 129

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 129
Study: 33779259

Group type: EXPERIMENTAL
Intervention: Inoculated with isolate DAL-59 (Diaporthe amygdali) using colonized agar plugs (3 mm diameter) inserted into 3 mm wounds.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group inoculated with uncolonized PDA plugs.
Number of subjects: 12
Study: 33236939

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr) plus guideline directed medical therapy (GDMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline directed medical therapy (GDMT) alone
Number of subjects: 0
Study: 36199248

Group type: EXPERIMENTAL
Intervention: Remdesivir plus usual care
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 1281
Study: 34543475

Group type: EXPERIMENTAL
Intervention: Xenograft blocks infused with BMP-2
Number of subjects: 24

Group type: COMPARATOR
Intervention: Autogenous bone blocks
Number of subjects: 24
Study: 35292423

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg once daily)
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Aspirin (100 mg daily)
Number of subjects: 7213

Group type: EXPERIMENTAL
Intervention: Rivaroxaban and Aspirin (both groups)
Number of subjects: 7213
Study: 33127308

Group type: EXPERIMENTAL
Intervention: Bilateral Distance (BD) partition method
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: D10 partition method
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional CV partition method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment
Number of subjects: 60
Study: 34378842

Group type: EXPERIMENTAL
Intervention: Evidence-based nursing interventions
Number of subjects: 78

Group type: COMPARATOR
Intervention: Routine nursing interventions (Control)
Number of subjects: 78
Study: 32534142

Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 520

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 520
Study: 35311481

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral pain management protocol
Number of subjects: 327
Study: 32633646

Group type: EXPERIMENTAL
Intervention: Hyper-muscular physique with 'evidence-based RT' information
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hyper-muscular physique with 'lift big-get big' information
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lean physique with 'lift big-get big' information
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 110
Study: 32428012

Group type: EXPERIMENTAL
Intervention: Communication training (2 x 2.25h) based on the MAAS‐Global‐D
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Control group (observational data)
Number of subjects: 1554
Study: 35674919

Group type: EXPERIMENTAL
Intervention: Prenatal morphine treatment (twice daily, s.c. from gestational days 11–18)
Number of subjects: 2
Study: 32125709

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: lifestyle intervention (physical activity and dietary supplementation with inorganic nitrate)
Number of subjects: 240

Group type: COMPARATOR
Intervention: optimal standard therapy (control group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Number of subjects: 240
Study: 35926542

Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Riociguat
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: BPA after riociguat (follow-up)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Riociguat after BPA (follow-up)
Number of subjects: 105

Group type: COMPARATOR
Intervention: First-line riociguat
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: First-line BPA
Number of subjects: 105
Study: 32335058

Group type: EXPERIMENTAL
Intervention: Aberration-free IOL
Number of subjects: 111

Group type: COMPARATOR
Intervention: Negative-spherical aberration IOL
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Aberration-free IOL in post-hyperopic LASIK eyes
Number of subjects: 111
Study: 34032729

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 220
Study: 36222961

Group type: EXPERIMENTAL
Intervention: Bulk-filling technique with X-tra fil (Voco)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Incremental technique with Filtek Bulk Fill (3M ESPE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Incremental technique with X-tra fil (Voco)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bulk-filling technique with Filtek Bulk Fill (3M ESPE)
Number of subjects: 20
Study: 34269426

Group type: EXPERIMENTAL
Intervention: Viloxazine ER 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viloxazine ER 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viloxazine ER 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viloxazine ER 200 mg (adolescents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viloxazine ER 400 mg (adolescents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viloxazine ER 600 mg (adolescents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Missed doses of viloxazine ER
Number of subjects: 0
Study: 32448254

Group type: EXPERIMENTAL
Intervention: High treatment expectations at baseline
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Previous substance use
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Therapist's role in recovery and readiness to change
Number of subjects: 327
Study: 35511322

Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy including electromyographic biofeedback for 8 weeks
Number of subjects: 140
Study: 34246277

Group type: EXPERIMENTAL
Intervention: Inpatient statin use (Atorvastatin was the most commonly prescribed, n = 205, 82%)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Inpatient statin use among patients with DM
Number of subjects: 922

Group type: COMPARATOR
Intervention: Non-statin group among patients without DM
Number of subjects: 922
Study: 32734790

Group type: EXPERIMENTAL
Intervention: Collagen dressing
Number of subjects: 64

Group type: COMPARATOR
Intervention: Physiological serum (PS) dressing
Number of subjects: 64
Study: 33710095

Group type: EXPERIMENTAL
Intervention: AFVP+IPS-SE (About Face Vocational Program plus Individualized Placement and Support, Supported Employment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AFVP (About Face Vocational Program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AFVP+IPS-SE
Number of subjects: 0

Group type: COMPARATOR
Intervention: AFVP
Number of subjects: 0
Study: 35959346

Group type: EXPERIMENTAL
Intervention: FTS combined with empathic care (Group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: FTS intervention (Group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional nursing intervention (Group C)
Number of subjects: 180
Study: 34024536

Group type: EXPERIMENTAL
Intervention: Structured dietary intervention based on the Mediterranean diet
Number of subjects: 55

Group type: COMPARATOR
Intervention: General dietary recommendations (SC group)
Number of subjects: 55
Study: 33199406

Group type: EXPERIMENTAL
Intervention: Qualitative exploration of adolescent expressions of sadness through semi-structured interviews
Number of subjects: 37
Study: 33624046

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800
Study: 32188322

Group type: EXPERIMENTAL
Intervention: Reciprocating gait orthosis (RGO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hip knee ankle foot orthosis (HKAFO)
Number of subjects: 22
Study: 34813125

Group type: EXPERIMENTAL
Intervention: HTK-N solution
Number of subjects: 42

Group type: COMPARATOR
Intervention: HTK solution
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Posttransplant graft and patient survival
Number of subjects: 42
Study: 33112004

Group type: EXPERIMENTAL
Intervention: Footbath (warm water for 20 minutes, one hour before sleeping, for 6 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (without intervention)
Number of subjects: 100
Study: 36163028

Group type: EXPERIMENTAL
Intervention: Music care®
Number of subjects: 0
Study: 35906457

Group type: EXPERIMENTAL
Intervention: Daily sleep quality
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Daily sleep duration
Number of subjects: 96
Study: 34462317

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 398

Group type: COMPARATOR
Intervention: Antithrombotic prophylaxis
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Thromboembolic events
Number of subjects: 398
Study: 35298282

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment, 2 treatments spaced 3 weeks apart
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heated Eye Mask (HEM), daily for 6 weeks (42 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both IPL and HEM treatments
Number of subjects: 60
Study: 33453739

Group type: EXPERIMENTAL
Intervention: milk‐milk‐milk exercise
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: emotional word repetition
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: milk‐to‐emotional word shaping
Number of subjects: 108

Group type: COMPARATOR
Intervention: control without intervention
Number of subjects: 108
Study: 34455106

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide gel with violet LED (3 sessions of 15 min each, with 7 days interval)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No change of the bleaching gel during each session (NBGR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 changes of the bleaching gel every 5 min for each session (BGR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (NBGR and BGR)
Number of subjects: 0
Study: 32706534

Group type: EXPERIMENTAL
Intervention: Vitamin D group (14,000 IU of vitamin D3 weekly for 3 years)
Number of subjects: 8851

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 8851

Group type: EXPERIMENTAL
Intervention: Vitamin D group
Number of subjects: 8851

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8851
Study: 34275632

Group type: EXPERIMENTAL
Intervention: Moderate milk level (MM) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower milk level (LM) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-step gradual weaning program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-step gradual weaning program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study: 33181634

Group type: EXPERIMENTAL
Intervention: Milrinone (group M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP) (group S)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroglycerin (NTG) (group N)
Number of subjects: 60
Study: 35594286

Group type: EXPERIMENTAL
Intervention: High-frequency chest-wall oscillating vest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oscillatory positive expiratory pressure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cough-clearance alone
Number of subjects: 10
Study: 34698768

Group type: EXPERIMENTAL
Intervention: Kinesio-taping (KT) applied medially, laterally, and dorsally to both limbs of the study group.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no KT applied).
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Kinesio-taping (KT) applied to the study group.
Number of subjects: 37
Study: 35504144

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Minimally-enhanced usual care
Number of subjects: 134
Study: 35589232

Group type: EXPERIMENTAL
Intervention: Standard patent hemostasis
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: ULTRA method
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Facilitated hemostasis with a hemostatic disc
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1469
Study: 32559403

Group type: EXPERIMENTAL
Intervention: Hall technique (HT)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Non-Hall technique (NHT)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Non-Hall technique (NHT) with GIC
Number of subjects: 295
Study: 32044871

Group type: EXPERIMENTAL
Intervention: Pre-hospital plasma
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (Standard-of-care)
Number of subjects: 160
Study: 35622812

Group type: EXPERIMENTAL
Intervention: Machine learning-based intervention (text message prompts)
Number of subjects: 2695
Study: 33827828

Group type: EXPERIMENTAL
Intervention: Targeted strengthening physiotherapist-led treatment
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standardised stretching physiotherapist-led treatment
Number of subjects: 164
Study: 32664175

Group type: EXPERIMENTAL
Intervention: Cervus and cucumis peptides (LG) combined with UC‐MSC
Number of subjects: 119

Group type: COMPARATOR
Intervention: Methotrexate tablets, leflunomide, and UC‐MSC
Number of subjects: 119
Study: 35485559

Group type: EXPERIMENTAL
Intervention: Combined ACL reconstruction and ALL augmentation with internal bracing (ALL‐IB)
Number of subjects: 68
Study: 33608045

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33 ± 1 °C for 24 hours (n=47)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33 ± 1 °C for 48 hours (n=52)
Number of subjects: 99
Study: 35596802

Group type: EXPERIMENTAL
Intervention: Hybrid telerehabilitation program (12-week PFMT program including 2 face-to-face sessions, 2-weekly video sessions, follow-up by physiotherapist, re-evaluation teleconsultation at 6 and 16 weeks, face-to-face consultation at 12 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional program (2 initial individual sessions followed by twice-weekly group classes, all consultations face-to-face)
Number of subjects: 58
Study: 33200257

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 50 mg once weekly
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 32921794

Group type: EXPERIMENTAL
Intervention: CBD (600 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study: 36348477

Group type: EXPERIMENTAL
Intervention: pTEAS (transcutaneous electrical acupoint stimulation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no electrical output)
Number of subjects: 90
Study: 35674985

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus 5 mg nalbuphine
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus 10 mg nalbuphine
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus 20 mg nalbuphine
Number of subjects: 280

Group type: COMPARATOR
Intervention: Ropivacaine (30 mL 0.1% ropivacaine + 0.9% normal saline)
Number of subjects: 280
Study: 32186691

Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Cognitive Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34861374

Group type: EXPERIMENTAL
Intervention: Veliparib monotherapy (300-400 mg twice daily)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo monotherapy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Veliparib during combination therapy and monotherapy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Veliparib
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 33789853

Group type: EXPERIMENTAL
Intervention: Lenient rate control strategy (<110 bpm at rest)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Strict rate control strategy (<80 bpm at rest)
Number of subjects: 350
Study: 32379680

Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT) applied on the sacral and suprapubic regions with the ligament technique
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sham tape (ST) applied on the trochanter major with no technique
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no tape application)
Number of subjects: 51
Study: 34968470

Group type: EXPERIMENTAL
Intervention: Focal boost to conventional fractionated external beam radiotherapy (EBRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation dose to the bladder (D2 cm3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation dose to the urethra (D0.1 cm3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation dose to the urethra and bladder
Number of subjects: 0
Study: 33772285

Group type: EXPERIMENTAL
Intervention: Genicular nerve blockade using revised targets (RT-group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Genicular nerve blockade using classical targets (CT-group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both protocols (RT and CT)
Number of subjects: 55
Study: 34825782

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg/day for 5 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Crizotinib 250 mg single dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both treatments (Esomeprazole and Crizotinib)
Number of subjects: 15
Study: 34127619

Group type: COMPARATOR
Intervention: Inhaled treprostinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambulatory inhaled nitric oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Riociguat
Number of subjects: 0
Study: 35393308

Group type: EXPERIMENTAL
Intervention: Cytosponge test
Number of subjects: 1750
Study: 32197246

Group type: EXPERIMENTAL
Intervention: Microsurgical treatment of IPL BAVM
Number of subjects: 6
Study: 34229473

Group type: EXPERIMENTAL
Intervention: Labor dance during the active phase of labor
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no labor dance)
Number of subjects: 120
Study: 32513480

Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control
Number of subjects: 55
Study: 32822216

Group type: EXPERIMENTAL
Intervention: Long Sprint Intervals (LSI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MIC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Short Sprint Intervals (SSI)
Number of subjects: 12
Study: 35776388

Group type: EXPERIMENTAL
Intervention: ReQoL-20
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: ReQoL measures
Number of subjects: 393
Study: 32681547

Group type: EXPERIMENTAL
Intervention: High protein/low glycaemic index diet (25/45/30En% protein/carbohydrate/fat, GI < 50)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Moderate protein/moderate glycaemic index diet (15/55/30En% protein/carbohydrate/fat, GI ≥ 56)
Number of subjects: 126
Study: 32811625

Group type: EXPERIMENTAL
Intervention: Evidence-based psychosocial interventions for cannabis use disorder
Number of subjects: 600
Study: 35012573

Group type: EXPERIMENTAL
Intervention: Endometrial injury (scratching group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (noninjury)
Number of subjects: 40
Study: 33827504

Group type: EXPERIMENTAL
Intervention: Respirable dust exposure
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Spirometry values
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Current working at twisting department, > 5 years of service duration, respiratory symptoms, and increased respirable dust exposure
Number of subjects: 207
Study: 36382987

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Vehicle lotion (control)
Number of subjects: 1614
Study: 34170647

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 1879

Group type: COMPARATOR
Intervention: Semaglutide 1 mg
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses)
Number of subjects: 1879

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 1879
Study: 32034480

Group type: EXPERIMENTAL
Intervention: Overexpression of CARM1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (Con-H1299, Con-PC14)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CARM1 supplementation in H1299 cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High expression of CARM1
Number of subjects: 0
Study: 35930557

Group type: EXPERIMENTAL
Intervention: Fact-box styled message comparing risks of COVID-19 and vaccine
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Timeline styled message describing the development process of COVID-19 mRNA vaccines
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Control group (no message)
Number of subjects: 1075
Study: 32426949

Group type: EXPERIMENTAL
Intervention: Protein quality-optimized RUSF (75 kcal/kg/day for up to 12 weeks)
Number of subjects: 1737

Group type: COMPARATOR
Intervention: Control RUSF (75 kcal/kg/day for up to 12 weeks)
Number of subjects: 1737

Group type: EXPERIMENTAL
Intervention: Protein quality-optimized RUSF
Number of subjects: 1737

Group type: COMPARATOR
Intervention: Control RUSF
Number of subjects: 1737